Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
GE Capital
AddedFeb 13, 2024
UpdatedJun 28, 2026
GE Capital

GE Capital

Operating

Norwalk-based financial services company, GE Capital Australia, providing diverse business services since 1981.

Location
Norwalk, CT, US
Founded
1932
Firm
Compare
Portfolio
Employees

Investments

Cerapedics
Cerapedics
Public

Total Raised

$205.7M

Rounds

13

Debt Financing$4MApril 2015
Debt Financing$9MApril 2014
LinkedIn
LinkedIn
Acquired Subsidiary

Total Raised

$26.4B

Rounds

11

Public$25MApril 2015
Usgi Medical
Usgi Medical

Total Raised

$81.5M

Rounds

6

Series Unknown$19.5MJanuary 2015
Debt Financing$9MJuly 2014
Spiracur
Spiracur
Public

Total Raised

$75.5M

Rounds

4

Debt Financing$16MNovember 2014
Schumacher Group
Schumacher Group

Total Raised

$120M

Rounds

1

Debt Financing$120MOctober 2014
Sintx Technologies
Sintx Technologies
Public

Total Raised

$196.3M

Rounds

16

Public$26MJuly 2014
Debt Financing$21.5MJanuary 2013
Del Taco
Del Taco
Public

Total Raised

$260M

Rounds

1

Debt Financing$260MApril 2014
AirXpanders
AirXpanders
Public

Total Raised

$150M

Rounds

16

Debt Financing$7MApril 2014
WKS Restaurant
WKS Restaurant

Total Raised

$43M

Rounds

1

Debt Financing$43MFebruary 2014
Chromatin
Chromatin

Total Raised

$122.3M

Rounds

10

Series E$36MJanuary 2014
Sonitus Medical
Sonitus Medical

Total Raised

$74.2M

Rounds

7

Debt Financing$10MSeptember 2013
View
View
Public

Total Raised

$2.6B

Rounds

21

Series E$60MJune 2013
ASI System Integration
ASI System Integration

Total Raised

$40M

Rounds

1

Debt Financing$40MMarch 2013
Cardiodx
Cardiodx

Total Raised

$337.3M

Rounds

12

Private Equity$58MAugust 2012
Private Equity$30.5MJuly 2012
Private Equity$60MMay 2011
C8 Medisensors
C8 Medisensors

Total Raised

$69.1M

Rounds

8

Series C$19MJune 2012
Redapt
Redapt

Total Raised

$40M

Rounds

1

Series Unknown$40MMarch 2012
BG Medicine
BG Medicine
Public

Total Raised

$107M

Rounds

10

Post Ipo Debt$15MMarch 2012
Saladax Biomedical
Saladax Biomedical

Total Raised

$54.9M

Rounds

9

Debt Financing$9MJune 2011
Datapipe
Datapipe
Acquired

Total Raised

$487.4M

Rounds

5

Debt Financing$176MMay 2011
Neovista
Neovista

Total Raised

$156.9M

Rounds

11

Debt Financing$20MMarch 2011